Pomalidomide

Pomalidomide is an oral immunomodulatory medicine belonging to the thalidomide analogue class. It is primarily used in selected treatment regimens for multiple myeloma, a cancer of plasma cells in the bone marrow, and is also approved in the United States for certain patients with Kaposi sarcoma. Pomalidomide acts through several mechanisms, including binding to cereblon, a component of a cellular protein complex that helps regulate the breakdown of specific proteins involved in cell growth and immune activity. These effects can inhibit malignant cell growth, alter signals that support tumour survival, and enhance immune-mediated activity against cancer cells. The medicine is supplied as capsules and is generally taken in repeated treatment cycles, often alongside dexamethasone or other anticancer medicines according to the indication and regional approval. Its role is particularly important in selected patients whose multiple myeloma has returned or progressed after previous treatments. Pomalidomide can cause serious adverse effects, including severe birth defects if used during pregnancy, low blood-cell counts, infections, and venous or arterial blood clots. Treatment therefore requires specialist supervision, strict pregnancy-prevention measures where applicable, and regular clinical and laboratory monitoring.

Pomalidomide was developed as an immunomodulatory derivative of thalidomide for the treatment of haematological malignancies. Its activity involves cereblon-mediated protein regulation and downstream effects on tumour cells and immune responses. The US Food and Drug Administration (FDA) first approved pomalidomide in February 2013 for selected adults with multiple myeloma whose disease had progressed after previous treatment. The European Medicines Agency (EMA) authorised Imnovid in the European Union on 5 August 2013 for relapsed and refractory multiple myeloma. European indications subsequently included combination treatment with bortezomib and dexamethasone for eligible adults previously treated with a regimen including lenalidomide. In the United States, the FDA also approved pomalidomide for certain adults with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy, when the patient is HIV-negative. The multiple myeloma evidence base includes the MM-003 study of pomalidomide with low-dose dexamethasone and the OPTIMISMM study evaluating pomalidomide with bortezomib and dexamethasone. Approved indications, combination regimens, and eligibility criteria differ by jurisdiction and should be checked against current local prescribing information.

Pomalidomide is used mainly in combination with other medicines to treat selected adults with multiple myeloma that has progressed despite previous therapy. In the United States, it is indicated with dexamethasone for adults who have received at least two prior treatments, including lenalidomide and a proteasome inhibitor, and whose disease progressed during or within 60 days after their most recent treatment. In the European Union, approved regimens include pomalidomide with dexamethasone for relapsed or refractory disease after specified previous therapies, as well as pomalidomide with bortezomib and dexamethasone for eligible adults previously treated with a regimen including lenalidomide. In the United States, pomalidomide is also indicated for adults with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy, when the patient is HIV-negative. It is not appropriate for every patient with these conditions; treatment selection depends on previous therapies, disease status, comorbidities, and the applicable regional approval.

Pomalidomide is taken orally as capsules, with the dose and schedule determined by the indication, combination regimen, organ function, and tolerability. For multiple myeloma treated with dexamethasone, the usual US starting dose is 4 mg once daily on days 1–21 of each 28-day cycle. In the European regimen combining pomalidomide with bortezomib and dexamethasone, pomalidomide is generally given on days 1–14 of repeated 21-day cycles, according to the approved product information. For the US-approved Kaposi sarcoma indication, the recommended dose is generally 5 mg once daily on days 1–21 of each 28-day cycle. Treatment is usually continued until disease progression or unacceptable toxicity, with dose interruptions or reductions when necessary. Capsules should be taken according to the prescribed instructions and swallowed whole. Missed doses, vomiting after a dose, renal impairment requiring dialysis, hepatic impairment, and interacting medicines require guidance from the treating team. Complete blood counts and other clinical assessments are essential during treatment.

Common adverse effects include low white blood cell counts, particularly neutropenia, anaemia, low platelet counts, fatigue, fever, constipation, diarrhoea, nausea, and peripheral swelling. Respiratory infections, including pneumonia, may occur, and some patients experience numbness, tingling, or pain in the hands and feet. The frequency and severity of side effects depend on the treatment combination, underlying illness, previous therapies, and individual health. Low blood counts can increase infection or bleeding risk and may require supportive treatment or dose modification. Patients should report persistent fever, unusual bruising, bleeding, worsening weakness, or new nerve symptoms promptly. Supportive care, laboratory monitoring, and adjustments made by the treating clinician can help manage adverse effects, but patients should not change or stop treatment without medical advice.

Pomalidomide carries major warnings for embryo-fetal toxicity and venous and arterial thromboembolism. Exposure during pregnancy can cause severe, life-threatening birth defects or fetal death; pregnancy is a contraindication, and strict pregnancy-prevention requirements apply. Serious blood disorders, including severe neutropenia, anaemia, and thrombocytopenia, may occur and can lead to infections or bleeding. Deep-vein thrombosis, pulmonary embolism, heart attack, and stroke have been reported, so thrombosis risk assessment and appropriate preventive measures are important. Serious infections, liver injury, severe skin reactions, and allergic reactions are additional concerns. Treatment may need to be interrupted, reduced, or discontinued for significant toxicity, worsening blood counts, thromboembolic events, or other clinically important complications. Patients should seek urgent medical assessment for sudden breathlessness, chest pain, one-sided leg swelling, new weakness or speech difficulties, uncontrolled bleeding, or severe allergic symptoms. The treating specialist should follow the current product label when deciding on treatment interruption or permanent discontinuation.

Before starting pomalidomide, clinicians should assess pregnancy status where relevant, complete blood counts, liver function, renal function, infection history, thromboembolic risk, and concomitant medicines. Pregnancy testing and contraception requirements must be followed through the applicable risk-management programme. Pomalidomide should not be used during pregnancy, and breastfeeding is not recommended during treatment. Patients with pre-existing liver disease, severe renal impairment, peripheral neuropathy, or significant cardiovascular risk factors may need closer monitoring or dose adjustment. Strong CYP1A2 inhibitors can increase pomalidomide exposure; the US prescribing information advises avoiding concomitant use or reducing the dose when co-administration is unavoidable, according to the current label. Medicines that increase bleeding or clotting risk should be reviewed carefully, particularly when anticoagulants or antiplatelet agents are being used. Vaccination and infection-prevention plans should be individualised, especially during combination cancer therapy. Patients should disclose all prescription medicines, non-prescription products, and supplements to their healthcare team.

Confirm the indication, previous treatment history, prescribed combination, and local approval criteria before dispensing pomalidomide. Review pregnancy-prevention requirements and ensure that applicable risk-management procedures are completed before treatment begins. Obtain baseline blood counts, liver and renal function tests, and a documented assessment of thromboembolic risk. Monitor complete blood counts frequently during the early treatment cycles and periodically thereafter; the US prescribing information and local protocols should guide the exact schedule. Assess the need for thrombosis prophylaxis based on the regimen and individual risk factors. Counsel patients to take capsules exactly as prescribed, avoid sharing the medicine, and follow the product-specific instructions for handling and disposal. Reinforce prompt reporting of fever, bleeding, symptoms of blood clots, or possible pregnancy. Pharmacists should check for interacting medicines, particularly strong CYP1A2 inhibitors, and verify dose adjustments for organ impairment. Coordination between haematology or oncology, pharmacy, nursing, and supportive-care teams supports safer treatment.